Descrizione immagine

Goran Westerberg, PhD, MTOPRA, Associate Professor


Positions Held  

2012 - Present

Owner and Director, La Crocina Pharmaceutical Consultants 
2004 - 2012

Director, Clinical & Regulatory Development, Siena Biotech SpA, Italy

2002 - 2004

Director, Pharmacokinetics, Pharmacia, Milan, Italy

2000 - 2002

R&D Interface Supervisor, Pharmacia, Milan, Italy

1997 - 2000

Senior Research Advisor, Pharmacia & Upjohn, Stockholm, Sweden 

1993 - 1997 

Associate Director, Uppsala PET Centre, Uppsala, Sweden

1988 - 1993 

Research Scientist,Uppsala PET Centre, Uppsala, Sweden





Associate Professor, Radiopharmacology, Uppsala University, Sweden 
1994 PhD, Radiopharmaceutical Chemistry, Uppsala University, Sweden
1992 MSc, Radiopharmaceutical Chemistry, Uppsala University, Sweden
BSc, Organic Chemistry,Uppsala University, Sweden
Descrizione immagine

About La Crocina


La Crocina Pharmaceutical Consultants offers high-quality consultancy and advisory services to the Life Sciences Sector, particularly regarding the early Clinical Development phases. La Crocina provides a helicopter view of all facets of the development process from Preclinical Candidate to the start of registrational studies, including Regulatory-, Business- and Project Management aspects.


Your Consultant

La Crocina is owned and managed by Goran Westerberg, PhD, MTOPRA, Associate Professor; over the past 25 years (and 550 clinical trials) in the pharmaceutical industry, I have matured a broad and varied experience in the early clinical development domain. Starting with 10 years in the clinical Contract Research world, I moved into Pharma in 1997 working in Sweden, the UK, Italy, Japan and the US.

My main interest and experience lies in pulling compounds out of Discovery and pushing them to clinical proof-of-concept; overall, I have taken 31 new compounds into first-in-human trials and worked across the anti-infective, CNS, oncology, urology, gynaecology, metabolic diseases and cardiovascular areas. I have also matured a significant experience of the licensing process, with more than 25 Due Diligence evaluations.